Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OMER – Omeros Corporation

Omeros Corporation
OMER
$3.77
Name : Omeros Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $220,894,480.00
EPSttm : -3.04
finviz dynamic chart for OMER
Omeros Corporation
$3.77
14.24%
$0.47

Float Short %

19.13

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

EPS Last/This Y

0.63

EPS This/Next Y

2.3

Price

3.77

Target Price

40.5

Analyst Recom

2

Performance Q

-50.78

Relative Volume

1.11

Beta

2.2

Ticker: OMER




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08OMER6.30.460.0332603
2025-05-09OMER6.170.460.8532711
2025-05-12OMER3.80.460.5733228
2025-05-13OMER4.430.450.9433972
2025-05-14OMER3.910.450.1134094
2025-05-15OMER3.950.430.2235732
2025-05-16OMER3.210.420.3936297
2025-05-19OMER3.310.330.4820570
2025-05-20OMER3.290.330.6921291
2025-05-21OMER3.110.340.1821573
2025-05-22OMER3.210.320.0021487
2025-05-23OMER3.150.320.3521605
2025-05-27OMER3.170.310.7621635
2025-05-28OMER3.130.280.7721235
2025-05-29OMER3.320.300.0822499
2025-05-30OMER3.090.300.0122643
2025-06-02OMER3.070.300.0522859
2025-06-03OMER3.150.291.3523339
2025-06-04OMER3.340.290.0623374
2025-06-05OMER3.30.280.0624154
2025-06-06OMER3.770.280.1024695
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08OMER6.3019.6- -2.28
2025-05-09OMER6.1819.6- -2.28
2025-05-12OMER3.8019.6- -2.28
2025-05-13OMER4.4319.6- -2.28
2025-05-14OMER3.9319.6- -2.28
2025-05-15OMER3.9419.6- -2.28
2025-05-16OMER3.2119.6- -2.28
2025-05-19OMER3.3219.6- -2.28
2025-05-20OMER3.2952.1- -2.28
2025-05-21OMER3.1152.1- -2.28
2025-05-22OMER3.2052.1- -2.28
2025-05-23OMER3.1552.1- -2.28
2025-05-27OMER3.1754.9- -2.07
2025-05-28OMER3.1254.9- -2.07
2025-05-29OMER3.3154.9- -2.07
2025-05-30OMER3.0954.9- -2.07
2025-06-02OMER3.0854.9- -2.07
2025-06-03OMER3.1454.9- -2.07
2025-06-04OMER3.3354.9- -2.07
2025-06-05OMER3.3054.9- -2.07
2025-06-06OMER3.7754.9- -2.07
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08OMER0.006.4319.22
2025-05-09OMER0.006.4319.22
2025-05-12OMER0.006.6816.46
2025-05-13OMER0.006.6816.46
2025-05-14OMER0.006.6816.46
2025-05-15OMER0.006.6816.46
2025-05-16OMER0.006.6816.46
2025-05-19OMER0.007.7016.38
2025-05-20OMER0.007.7016.38
2025-05-21OMER0.007.7016.38
2025-05-22OMER0.007.7016.38
2025-05-23OMER0.007.7016.38
2025-05-27OMER0.002.8416.38
2025-05-28OMER0.002.8419.13
2025-05-29OMER0.002.8419.13
2025-05-30OMER0.002.8419.13
2025-06-02OMER0.003.2619.13
2025-06-03OMER0.003.2619.13
2025-06-04OMER0.003.2619.13
2025-06-05OMER0.003.2619.13
2025-06-06OMER0.003.2619.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.51

Avg. EPS Est. Next Quarter

-0.5

Insider Transactions

Institutional Transactions

3.26

Beta

2.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

26

Sentiment Score

20

Actual DrawDown %

85.2

Max Drawdown 5-Year %

-95.4

Target Price

40.5

P/E

Forward P/E

12.78

PEG

P/S

P/B

P/Free Cash Flow

EPS

-2.64

Average EPS Est. Cur. Y​

-2.07

EPS Next Y. (Est.)

0.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.11

Return on Equity vs Sector %

47.6

Return on Equity vs Industry %

65.6

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.21

EBIT Estimation

Omeros Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 202
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading